(Q33263803)

24 July 2017

1 reference

title

A review of drug options in age-related macular degeneration therapy and potential new agents (English)

1 reference

24 July 2017

1 reference

Jonathan Yeoh

1

1 reference

24 July 2017

Joanne Sims

series ordinal

2

1 reference

24 July 2017

Robyn H Guymer

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Pharmacotherapy

24 July 2017

published in

1 reference

24 July 2017

volume

7

1 reference

24 July 2017

issue

17

1 reference

24 July 2017

page(s)

2355-2368

1 reference

Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Age-specific causes of bilateral visual impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Symptomatic abnormalities of dark adaptation in patients with age-related Bruch's membrane change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

A simplified severity scale for age-related macular degeneration: AREDS Report No. 18

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Genetic association of apolipoprotein E with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

The epidemiology of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Risk factors for incident age-related macular degeneration: pooled findings from 3 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Keypathophysiologic pathways in age-related macular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Inhibitors of ocular neovascularization: promises and potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

New treatments in age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Serological Association Between Chlamydia pneumoniae Infection and Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Photosensitizers in photodynamic therapy of choroidal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Choroidal neovascular membranes treated with photodynamic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Angiostatic steroids. Method of discovery and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Should corticosteroids be considered as part of the standard care with photodynamic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

neovascular age-related macular degeneration: Natural History and Treatment Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Impaired expression of thrombospondin-1 in eyes with age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Exudative macular degeneration and intravitreal triamcinolone. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Blockade of nitric-oxide synthase reduces choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Does dietary lutein and zeaxanthin increase the risk of age related macular degeneration? The Melbourne Visual Impairment Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Risk of macular degeneration in users of statins: cross sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

The association between statin use and age related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2355

10.1517/14656566.7.17.2355

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference